Juliane S. Lanza

Chatenay-sur-seine, 92296, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications

Re-sensitization of antimony-resistant Leishmania by highly potent SbV-porphyrin through the involvement of ERG6-coding gene.

Re-sensitization of antimony-resistant Leishmania by highly potent SbV-porphyrin through the involvement of ERG6-coding gene.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: December 26, 2024

Targeting Langerhans cells via skin delivery of HIV Envelope enhances the antibody response to vaccination.

Targeting Langerhans cells via skin delivery of HIV Envelope enhances the antibody response to vaccination.

Journal: NPJ vaccines
Published: December 25, 2024

Supramolecular assemblies from antimony(V) complexes for the treatment of leishmaniasis.

Supramolecular assemblies from antimony(V) complexes for the treatment of leishmaniasis.

Journal: Biophysical reviews
Published: March 28, 2023

Nanoassemblies from Amphiphilic Sb Complexes Target Infection Sites in Models of Visceral and Cutaneous Leishmaniases.

Nanoassemblies from Amphiphilic Sb Complexes Target Infection Sites in Models of Visceral and Cutaneous Leishmaniases.

Journal: Pharmaceutics
Published: July 13, 2022

Low Adenovirus Vaccine Doses Administered to Skin Using Microneedle Patches Induce Better Functional Antibody Immunogenicity as Compared to Systemic Injection.

Low Adenovirus Vaccine Doses Administered to Skin Using Microneedle Patches Induce Better Functional Antibody Immunogenicity as Compared to Systemic Injection.

Journal: Vaccines
Published: January 20, 2021

Intranasal vaccine from whole Leishmania donovani antigens provides protection and induces specific immune response against visceral leishmaniasis.

Intranasal vaccine from whole Leishmania donovani antigens provides protection and induces specific immune response against visceral leishmaniasis.

Journal: PLoS neglected tropical diseases
Published: December 20, 2020

Targeting human langerin promotes HIV-1 specific humoral immune responses.

Targeting human langerin promotes HIV-1 specific humoral immune responses.

Journal: PLoS pathogens
Published: November 13, 2020

A TLR9-adjuvanted vaccine formulated into dissolvable microneedle patches or cationic liposomes protects against leishmaniasis after skin or subcutaneous immunization.

A TLR9-adjuvanted vaccine formulated into dissolvable microneedle patches or cationic liposomes protects against leishmaniasis after skin or subcutaneous immunization.

Journal: International journal of pharmaceutics
Published: December 16, 2019

Nanostructured Systems Improve the Antimicrobial Potential of the Essential Oil from Cymbopogon densiflorus Leaves.

Nanostructured Systems Improve the Antimicrobial Potential of the Essential Oil from Cymbopogon densiflorus Leaves.

Journal: Journal of natural products
Published: December 10, 2019

Recent advances in amphotericin B delivery strategies for the treatment of leishmaniases.

Recent advances in amphotericin B delivery strategies for the treatment of leishmaniases.

Journal: Expert opinion on drug delivery
Published: August 22, 2019

Combination oral therapy against Leishmania amazonensis infection in BALB/c mice using nanoassemblies made from amphiphilic antimony(V) complex incorporating miltefosine.

Combination oral therapy against Leishmania amazonensis infection in BALB/c mice using nanoassemblies made from amphiphilic antimony(V) complex incorporating miltefosine.

Journal: Parasitology research
Published: January 25, 2019

Growth arrested live-attenuated Leishmania infantum KHARON1 null mutants display cytokinesis defect and protective immunity in mice.

Growth arrested live-attenuated Leishmania infantum KHARON1 null mutants display cytokinesis defect and protective immunity in mice.

Journal: Scientific reports
Published: March 27, 2018
Showing 1-12 of 14

Last Updated: 09/26/2026